Reduced density of ADAM 12-immunoreactive oligodendrocytes in the anterior cingulate white matter of patients with schizophrenia

World Journal of Biological Psychiatry

Volumn 11, Issue 3, 2010, Pages 556-566

  Farkas, Nadine ^a   Lendeckel, Uwe ^b   Dobrowolny, Henrik ^a   Funke, Sieglinde ^a   Steiner, Johann ^a   Keilhoff, Gerburg ^a   Schmitt, Andrea ^c   Bogerts, Bernhard ^a   Bernstein, Hans Gert ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b UNIVERSITY OF GREIFSWALD   (Germany)

^c UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

ADAM (A disintegrin and metalloprotease) 12; Immunohistochemistry; Morphometry; Oligodendroglia; Prefrontal cortex; Schizophrenia

Indexed keywords

ADAM12 PROTEIN; HALOPERIDOL; METALLOPROTEINASE; UNCLASSIFIED DRUG; ADAM 12 PROTEIN; ADAM PROTEIN; MEMBRANE PROTEIN;

ADULT; AGED; ANIMAL CELL; ANIMAL CELL CULTURE; ARTICLE; BRAIN SIZE; CADAVER; CINGULATE GYRUS; CLINICAL ARTICLE; DENSITY; FEMALE; FRONTAL CORTEX; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; OLIGODENDROGLIA; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHIZOPHRENIA; WESTERN BLOTTING; WHITE MATTER; CHROMOSOME 10; GENE EXPRESSION REGULATION; GENETICS; MIDDLE AGED; PATHOLOGY; PREFRONTAL CORTEX; REFERENCE VALUE; SIGNAL TRANSDUCTION; ANTERIOR CINGULATE; CELL DENSITY; CHROMOSOME 10Q; CONTROLLED STUDY; IMMUNOFLUORESCENCE; IMMUNOLOCALIZATION; IMMUNOREACTIVITY; MOLECULAR PATHOLOGY; PROTEIN ANALYSIS; PROTEIN METABOLISM;

ADAM PROTEINS; BLOTTING, WESTERN; CHROMOSOMES, HUMAN, PAIR 10; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GYRUS CINGULI; HUMANS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; OLIGODENDROGLIA; PREFRONTAL CORTEX; REFERENCE VALUES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SCHIZOPHRENIA; SIGNAL TRANSDUCTION;

EID: 77953644886     PISSN: 15622975     EISSN: 18141412     Source Type: Journal    
DOI: 10.3109/15622970903497936     Document Type: Article

References (74)

1. Atfi A, Dumont E, Colland F, Bonnier D, L'Helgoualc'h A, Prunier C, et al. 2007. The disintegrin and metalloproteinase ADAM12 contributes to TGF-ß signaling through interaction with the type II receptor. J Cell Biol 178: 201-208.
2. Akanji AO, Ohaeri JU, Al-Shammri SA, Fatania HR. 2007. Associations of blood levels of insulin-like growth factor (IGF)-I, IGF-II and IGF binding protein (IGFBP)-3 in schizophrenic Arab subjects. Clin Chem Lab Med 45:1229-1231.
3. Arndt M, Lendeckel U, Röcken C, Nepple K, Wolke C, Spiess A, et al. 2002. Altered expression of ADAMs (A Disintegrin and Metalloproteinase) in fi brillating human atria. Circulation 105:720-725.
4. Asakura M, Kitakaze M, Takashima S, Liao Y, Ishikura F, Yoshinaka T, et al. 2002. Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metallopro-teinase inhibitors as a new therapy. Nat Med 8:35-40.
5. Bernstein H-G, Stanarius A, Baumann B, Henning H, Krell D, Danos P, et al. 1998. Nitric oxide synthase-containing neurons in the human hypothalamus: Reduced number of immunoreac-tive cells in the paraventricular nucleus of depressive patients and schizophrenics. Neuroscience 83:967-1875
6. Bernstein H-G, Baumann B, Danos P, Diekmann S, Bogerts B, Gun-delfi nger ED, Braunewell K-H.1999. Regional and cellular distribution of neural visinin-like protein immunoreactivities (VILIP-1 and vilip-3) in human brain. J Neurocytol 28:655-662.
7. Bernstein H-G, Keilhoff G, Bukowska A, Ziegeler A, Funke S, Dobrowolny H, et al. 2004. ADAM (a disintegrin and metal-loprotease) 12 is expressed in rat and human brain and localized to oligodendrocytes. J Neurosci Res 75:353-360
8. Bernstein H-G, Lendeckel U, Dobrowolny H, Stauch R, Steiner J, Grecksch G, et al. 2008. Beacon-like/ubiquitin-5-like immuno-reactivity is highly expressed in human hypothalamus and increased in haloperidol-treated schizophrenics and a rat model of schizophrenia. Psychoneuroendocrinology 33: 340-351.
9. Bernstein H-G, Steiner J, Bogerts B. 2009. Glial cells in schizophrenia: Pathophysiological signifi cance and possible consequences for therapy. Expert Rev Neurother 9:1059-1071.
10. Bulyaeva KB, Glatt SJ, Bulyaev OA, Pavlova TA, Tsuang MT. 2007. Genome-wide linkage scan of schizophrenia: a cross-isolate study. Genomics 89:167-177.
11. Byne W, Kidkardnee S, Tatusov SA, Yiannoulos G, Buchsbaum MS, Haroutunian V. 2006. Schizophrenia-associated reduction of neuronal and oligodendrocyte numbers in the anterior principal thalamic nucleus. Schizophr Res 85:245-253.
12. Chissoe S, Ehm M, Jean St. P. 2008. Genes associated with schizophrenia. US Patent Application 20080176239:p.42.
13. Cadet JL, McCoy MT, Ladenheim B. 2002. Distinct gene expression signatures in the striata of wild-type and heterozygous c-fos knockout mice following methamphetamine administration: Evidence from cDNA array analyses. Synapse 44:211-226.
14. Cao Y, Zhao Z, Gruszczynska-Biegala J, Zolkiewska A. 2003. Role of metalloprotease disintegrin ADAM12 in determination of quiescent reserve cells during myogenic differentiation in vitro. Mol Cell Biol 23:6725-6738.
15. Chissoe S, Ehm MG, Jean St. P. 2008. Genes associated with schizophrenia. United States Patent Application 20080176239, p 42.
16. Cruz DA, Weaver CL, Lovallo EM, Melchitzky DS, Lewis DA. 2009. Selective alterations in postsynaptic markers of Chandelier cell inputs to cortical pyramidal neurons in subjects with schizophrenia. Neuropsychopharmacology 34:2112-2124
17. Danos P, Baumann B, Krämer K, Bernstein H-G, Stauch R, Krell D, et al. 2003. Volumes of association thalamic nuclei in schizophrenia: a postmortem study. Schizophr Res 60:141-155.
18. Davis KL, Stewart DG, Friedman JI, Buchsbaum M, Harvey PD, Hof PR, et al. 2003. White matter changes in schizophrenia: evidence for myelin-related dysfunction. Arch Gen Psychiatry 60: 443-456.
19. Dyczynska E, Sun D, Yi H, Sehara-Fujisawa A, Blobel CP, Zolkiewska A. 2007. proteolytic processing of delta-like 1 by ADAM proteases. J Biol Chem 282:436-444.
20. Edwards DR, Handsley MM, Pennington CJ.2008. The ADAM metalloproteinases, Mol Aspects Med 29:258-289.
21. Ewald H, Flint TJ, Jorgensen TH, Wang AG, Jensen P, Vang M, et al. 2002. Search for a shared segment on chromosome 10q26 in patients with bipolar affective disorder or schizophrenia from the Faroe Islands. Am J Med Genet 114:196-204.
22. Fornito Y, Yücel M, Wood SJ, Pantelis C. 2009. Anatomical abnormalities of the anterior cingulate cortex in schizophrenia: bridging the gap between neuroimaging and neuropathology. Schizophr Bull 35:973-993.
23. Futamura T, Toyooka K, Iritani S, Niizato S, Nakamura R, Tsuchiya K, et al. 2002. Abnormal epression of epidermal growth factor and its receptor in the forebrain and serum of schizophrenic patients, Mol Psychiatry 7: 673-682.
24. Gregg JR, Herring NR, Naydenov AV, Hanlin RP, Konradi C. 2009. Downregulation of oligodendrocyte transcripts is associated with impaired prefrontal cortex functions in rats. Schizo-phr Res 113:277-287
25. Hakak Y, Walker JR, Li C, Wong WH, Davis KL, Buxbaum JD, et al. 2001. Genome-wide expression analysis reveals dysregu-lation of myelination-related genes in chronic schizophrenia. Proc Natl Acad Sci USA 98: 4746-4751.
26. Harold D, Jehu L, Turic D, Hollingworth P, Moore P, Summerhaves P, et al. 2007. Interaction between the ADAM12 and SH3MD1 genes may confer susceptibility to late-onset alzheimer's disease. Am J Med Genet B Neuropsychiatr Genet 144: 448-452.
27. Hänninen K, Katila H, Anttila S, Rontu R, Maaskola J, Hurme M, Lehtimäki T. 2007. Epidermal grwoth factor a61g polymorphism is associated with the age of onset of schizophrenia in male patients. J Psychiatry Res 41: 8-14.
28. Hof PR, Haroutunian V, Copland C, Davis KL, Buxbaum JD. 2002. Molecular and cellular evidence for an oligodendrocyte abnormality in schizophrenia. Neurochem Res 27: 1193-1200.
29. Hof PR, Haroutunian V, Friedrich VL Jr, Byne W, Buitron C, Perl DP, Davis KL. 2003. Loss and altered spatial distribution of oligodendrocytes in the superior frontal gyrus in schizophrenia. Biol Psychiatry 53:1075-1085.
30. Höistad M, Segal D, Takahashi N, Sakurai T, Buxbaum JD, Hof PR. 2009. Linking white and grey matter in schizophrenia: oligodendrcyte and neuron pathology in the prefrontal cortex. Front Neuroanat 3:9.
31. Horiuchi K, Le Gall S, Schulte M, Yamaguchi T, Reiss K, Murphy G, et al. 2007. Substrate selectivity of epidermal growth factor-receptor ligand sheddases by phorbol esters and calcium infl ux. Mol Biol Cell 18:176-188.
32. Hung CC, Chen YH, Tsai MT, Chen CH. 2001. Systematic search for mutations in the human tissue inhibitors of metalloprotei-nases-3 (TIMP-3) gene on chromosome 22 and association study with schizophrenia. Am J Med Genet 105: 275-278.
33. Iossifov J, Zheng T, Baron M, Gilliam TC, Rzhetsky A. 2008. Genetic-linkage mapping of complex hereditary disorders to a whole-genome molecular-interaction network, Genome Res 18:1150-1161.
34. Ito N, Nomura S, Iwase A, Ito T, Kikkawa F, Tsujimoto M, et al. 2004. ADAMs, a disintegrin and metalloproteinases, mediate shedding of oxytocinase. Biochem Biophys Res Commun 314:1008-1013.
35. Ivo R, Schulze TG, Schumacher J, Kesper K, Müller DJ, Kremer I, et al. 2006. No evidence for association between Notch4 and schizophrenia in a large family-based and case-control association analysis. Psychiatr Genet 16:197-203.
36. Jacobsen J, Wewer UM. 2009. Targeting ADAM12 in human disease: head, body or tail? Curr Pharm Des 15:2300-2310.
37. Jacobsen J, Visse R, Sørensen HP, Enghild JJ, Brew K, Wewer UM, Nagase H. 2007. Catalytic properties of ADAM12 and its domain deletion mutants. Biochemistry 47:537-547.
38. Kalkman HO. 2009. Altered growth factor signalling pathways as the basis of aberrant stem cell maturation in schizophrenia. Pharmacol Ther 121: 115-121.
39. Katsel P, Davis KL, Li C, Tan W, Greenstein E, Kleiner Hoffman LG, Haroutunian V. 2008. Abnormal indices of cell cycle activity in schizophrenia and their potential association with oli-godendrocytes. Neuropsychopharmacology 33:2993-3009.
40. Kirkpatrick B, Messias NC, Conley RR, Roberts RC. 2003. Interstitial cells of the white matter in the dorsolateral prefrontal cortex in defi cient and nondefi cient schizophrenia. J Nerv Ment Dis 191: 563-567.
41. Kodama T, Ikeda E, Okada A, Ohtsuka T, Shimoda M, Shiomi T, et al. 2004. ADAM12 Is selectively overexpressed in human glioblastomas and is associated with glioblastoma cell proliferation and shedding of heparin-binding epidermal growth factor. Am J Pathol 165:1743-1753.
42. Kompus K, Hugdahl K, Marklund P, Nyberg L. 2009. Distinct control networks for cognition and emotion in the prefrontal cortex. Neurosci Lett 467:76-80.
43. Konopaske GT, Dorph-Petersen KA, Sweet RA, Pierri JN, Zhang W, Sampson AR, Lewis DA. 2008. Effect of chronic antipsy-chotic exposure on astrocyte and oligodendrocyte numbers in macaque monkeys. Biol Psychiatry 63:759-765.
44. Kurisaki T, Masuda A, Sudo K, Sakagami J, Higashiyama S, Matsuda Y, et al. 2003. Phenotypic analysis of Meltrin alpha (ADAM12)-defi cient mice: involvement of Meltrinalpha in adipogenesis and myogenesis. Mol Cell Biol 23:55-61.
45. Kveiborg M, Albrechtsen R, Couchman JR, Wewer UM. 2008. Cellular roles of ADAM12 in health and disease. Int J Biochem Cell Biol 40:1685-1702.
46. Laigaard J, Sørensen T, Fröhlich C, Pedersen BN, Christiansen M, Schiøtt K, et al. 2003. ADAM12: a novel fi rst-trimester maternal serum marker for Down syndrome. Prenat Diagn 23:1086-1091.
47. Lin J, Luo J, Redies C. 2008. Differential expression of fi ve members of the ADAM family in the developing chicken brain. Neuroscience 157: 360-375.
48. Maier O, van der Heide T, Johnson R, de Vries H, Baron W, Hoekstra D. 2006. The function of neurofascin155 in oli-godendrocytes is regulated by metalloprotease-mediated cleavage and ectodomain shedding. Exp Cell Res 312:500-511.
49. Loechel F, Fox JW, Murphy G, Albrechtsen R, Wewer UM. 2000. ADAM-12-S cleaves IGFBP-3 and IGFBP-5 and is inhibited by TIMP-3. Biochem Biophys Res Commun 278:511-515.
50. Mai JK, Assheuer J, Paxinos G. 2003. Atlas of the human brain. San Diego, CA: Academic Press.
51. Manoach DS, Ketwaroo GA, Polli FE, Thakkar KN, Barton JJS, Goff DC, et al. 2007. Reduced microstructural integrity of the white matter underlying anterior cingulate cortex is associated with increased saccadic latency in schizophrenia. Neuroimage 37:599-610.
52. Malinin NL, Wright S, Seubert P, Schenk D, Griswold-Prenner I. 2005. Amyloid-beta neurotoxicity is mediated by FISH-adapter protein and ADAM12 metalloprotease activity. Proc Natl Acad Sci USA 22: 3058-3063.
53. Martins-de-Souza D, Gattaz WF, Schmitt A, Maccarone G, Hunyadi-Gulý as E, Eberlein MN, et al. 2009. Proteomic analysis of dorsolateral prefrontal cortex indicates the involvement of cytoskeleton, oligodendrocyte, energy metabolism and new potential markers in schizophrenia. J Psychiatr Res 43:978-986.
54. Mayhew MH. 1992. A review of recent advances in stereology for quantifying neural structure. J Neurocytol 21: 313-328.
55. Moon HJ, Yim SV, Lee WK, Jeon YW, Kim YH, Ko YJ, et al. 2006. Identifi cation of DNA copy-number aberrations by array-comparative genomic hybridization in patients with schizophrenia. Biochem Biophys Res Commun 344:531-539.
56. Nadri C, Bersudsky Y, Belmaker RH, Agam G. 2007. Elevated urinary ADAM12 protein levels in lithium-treated bipolar patients. J Neural Transm 114:473-477.
57. Park N, Juo SH, Cheng R, Liu L, Loth JE, Lilliston B, et al. 2004. Linkage analysis of psychosis in bipolar pedigrees suggests novel putative loci for bipolar disorder and shared susceptibility with schizophrenia. Mol Psychiatry 9:1091-1099.
58. Rankinen T, Zuberi A, Chagnon YC, Weisnagel SJ, Argyropoulos G, Walts B, et al. 2006. The human obesity gene map: the 2005 update. Obesity 14:529-644
59. Schmitt A, Steyskal C, Bernstein H-G, Schneider-Axmann T, Parlapani E, Schaeffer EL, et al. 2009. Stereologic investigation of the posterior part of the hippocampus in schizophrenia. Acta Neuropathol 117:395-407.
60. Schmitt A, Otto S, Jatzko A, Ruf M, Demirakca T, Tost H, et al. 2009. Parieto-prefrontal dysfunction during visuo-auditory information processing in elderly, chronic schizophrenic patients and medication effects. Rev Psiquiatr Clin 36:89-96.
61. Segal D, Koschnick JR, Slegers LH, Hof PR. 2007. Oligodendro-cyte pathophysiology: a new view of schizophrenia. Int J Neu-ropsychopharmacol 10:503-511.
62. Segal D, Schmitz C, Hof PR. 2009. Spatial distribution and density of oligodendrocytes in the cingulum bundle are unaltered in schizophrenia. Acta Neuropathol 117:385-394.
63. Selemon LD, Mrzljak J, Kleinman JE, Herman MM, Goldman-Rakic PS. 2003. Regional specifi city in the neuropathologic substrates of schizophrenia: a morphometric analysis of Broca's area 44 and area 9. Arch Gen Psychiatry 60:69-77.
64. Sherman DL, Tait S, Melrose S, Johnson R, Zonta B, Court FA, et al. 2005. Neurofascins are required to establish axonal domains for saltatory conduction. Neuron 48:737-742
65. Stark AK, Uylings HBM, Sanz-Arigita E, Pakkenberg B. 2004. Glial cell loss in the anterior cingulate cortex, a subregion of the prefrontal cortex, in subjects with schizophrenia. Am J Psychiatry 161:4882-4888
66. Steiner J, Mawrin C, Ziegeler A, Bielau H, Ullrich O, Bernstein H-G, Bogerts B. 2006. Distribution of HLA-DR positive microglia in schizophrenia refl ects impaired cerebral lateraliza-tion. Acta Neuropathol 112:305-316.
67. Steiner J, Bernstein H-G, Bogerts B, Gos T, Richter-Landsberg C, Wunderlich MT, Keilhoff G. 2008. S100B is expressed in, and released from,OLN-93 oligodendrocytes: Infl uence of serum and glucose deprivation, Neuroscience 154:496-503.
68. Uranova NA, Orlovskaya DD, Vikhreva OV, Zimina IS, Rakhmanova VI. 2001. Morphometric study of ultrastructural changes in oligodendroglial cells in the postmortem brain in endogenous psychoses. Vestn Ross Akad Med Nauk 7:42-48.
69. Uranova NA, Vostrikov VM, Orlovskaya DD, Rachmanova VI. 2004. Oligodendroglial density in the prefrontal cortex in schizophrenia and mood disorders: a study from the Stanley Neuropathology Consortium. Schizophr Res 67:269-275.
70. Vostrikov VM, Uranova NA, Orlovskaya DD. 2007. Defi cit of perineuronal oligodendrocytes in the prefrontal cortex in schizophrenia and mood disorders. Schizophr Res 94:273-280.
71. Wang Z, Wei J, Zhang X, Guo Y, Xu Q, Liu S, et al. 2006. A review and re-evaluation of an association between the Notch4 locus and schizophrenia (2006) Am J Med Genet B Neuropsychiatr Genet 141B:902-906.
72. Wewer UM, Albrechtsen R, Engvall E. 2005. ADAM12: The long and the short of it. In: Proteases in Health and Disease. The ADAM family of proteases. Nigel NM, Lendeckel U, editors. New York: Springer. p 123-146.
73. Wu M-K, Wang C-K, Bai Y-A, Huang CY, Lee SD. 2007. Outcomes of obese, clozapine-treated inpatients with schizophrenia placed on a six-month diet and physical activity program. Psychiatr Serv 58:544-550.
74. Yamada Y, Esaki T, Mizutani T. 1999. Intracranial cavity volume can be accurately estimated from the weights of intracranial contents: confi rmation by the dental plaster casting method. Neuropathol Appl Neurobiol 25:341-344.